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Background: Exact role of the inﬂammation in osteoarthritis is still unclear, but it is thought to originate
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Objective: To determine the effect of CD30þ T lymphocytes on the development of osteoarthritis by
comparing the lesion depth and synovial CD30þ count in patients with chondral lesions undergoing
knee joint arthroscopy.
Design: A total of 79 patients with chondral lesions detected during arthroscopy were categorized in
4 different groups based on chondral lesion classiﬁcation. CD30þ lymphocyte counts were calculated
using ﬂow cytometry on synovial ﬂuid samples obtained at the time of initial entrance into the joint and
compared between the groups. In addition, biopsy samples obtained from the suprapatellar bursa were
stained for histologic examination to identify existence of CD30þ lymphocytes in the synovium.
Results: Although there were no signiﬁcant differences between the ﬁrst 3 groups in terms of synovial
ﬂuid CD30þ lymphocyte counts, patients in Group IV had signiﬁcantly higher counts (6.2 8 [2.48] vs 2.51
[1.84], 2.97 [2.40], and 3.80 [2.07], respectively; P o 0.05). Except for a single patient with a Grade III
chondral lesion, there were no cases of CD30 positivity in synovial tissue. Also there was a correlation
between CD30 levels and chondral lesion depth when controlled for age.
Conclusions: Our results indicate higher CD30þ lymphocyte counts in patients with modiﬁed Outer-
bridge Grade IV chondral lesions than in other groups. The origin of the CD30þ lymphocytes may not be
the synovial tissue per se. Thus, it was hypothesized that the injured chondral tissues and the associated
subchondral structures might have been the source of CD30þ lymphocytes with a possible inﬂuence on
the development of osteoarthritis.
& 2013. The Authors. Published by Elsevier Inc.Open access under CC BY-NC-SA license.Introduction
Osteoarthritis (OA) is not only the most common form of joint
disease but also a major cause of disability. Knee is the most
frequently involved joint. The etiology is not yet fully under-
stood.1,2 OA is a heterogeneous disease.3 Rheumatologists gener-
ally consider OA to be a noninﬂammatory disease,3 although
patients with OA often exhibit inﬂammatory inﬁltrates in the
synovial membrane. These inﬁltrates mostly consist of T cells
and macrophages.4–10 Recently Skapenko et al11 reported that T
cells and cytokines are not only present in inﬂammatory diseases,
but also signiﬁcantly contribute to the perpetuation of chronicr Inc.
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Open access under CC BY-NC-SA liceinﬂammation such as OA. The exact role of the inﬂammation in OA
is still unclear, but it is thought to originate from synovitis due to
microcrystals or breakdown products of the cartilage.3
T lymphocytes represent the single most important cell type for
immune functions and are responsible for speciﬁc immunity, which
is regulated by nonantibody-dependent cells involved in the proc-
ess. T cell populations are not homogenous and consist of different
subgroups, each with a speciﬁc function and structure. In addition to
common surface antigens found in all T lymphocytes (such as CD2,
CD3, and CD5), other surface molecules also exist that are used to
discriminate different T lymphocyte subgroups.4–12 The CD30 gene
is located on chromosome 1 at 1p36. It appears to be a lymphoid
activation gene and is part of the nerve growth factor/tumor
necrosis factor superfamily. The protein product is a 120 kDa
transmembrane glycoprotein. Its ligand, CD30L, has homology to
tumor necrosis factor. The transmembrane glycoprotein is often
referred to as the true CD30 antigen.13 CD30 is a costimulatory
molecule that plays an important role in the generation of T cell
responses and regulation of the balance between Th1- and Th2-type
immune responses.14 Reactive inﬂammatory disorders may containnse.
Table I
CD30 counts in the groups adjusted for age.
Group I
(n ¼ 19)
Group II
(n ¼ 15)
Group III
(n ¼ 22)
Group IV
(n ¼ 23)
F P
Mean % (SD)
CD30 2.51 (1.84) 2.97 (2.40) 3.80 (2.07) 6.28 (2.48) 12.3 0.001
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disorders clinically or histologically.15
Our study examines for the ﬁrst time the role of CD30þ T
lymphocytes in the pathogenesis of OA among 79 patients with
cartilage damage. CD30þ T lymphocyte count was determined in
joint ﬂuid samples from 79 patients undergoing knee arthroscopy;
presence of CD30þ T lymphocytes in synovial tissues was
explored and the association between CD30þ T lymphocyte count
and the severity of arthroscopic chondral lesions was evaluated.Methods
Seventy-nine patients (38 men and 41 women) attending out-
patient clinics due to OA and meniscopathy were included in this
study. Patients with rheumatologic conditions were excluded.
Arthroscopy was performed in 37 right and 42 left knees. During
the creation of an access point for arthroscopy, a 1.5-cc joint ﬂuid
sample was obtained in test tubes containing EDTA. Subsequently 2
mL DakoCytomation (Carpinteria, CA) monoclonal antibody CD30
Clone Ber-H2 was added into the tube and the percentage of
CD30þ T lymphocytes was determined through cell count of
labeled lymphocytes using an Epics XL-MCL device (Beckman
Coulter Inc, Brea, CA). Then, during arthroscopy, synovial biopsy
samples were obtained from the suprapatellar bursa and stained
immunohistochemically for the presence of CD30þ T lymphocytes.
We used anaplastic large cell lymphoma tissue as a positive control
for CD30 immunohistochemistry. Chondral lesions were examined
during arthroscopy and were graded using the modiﬁed Outer-
bridge classiﬁcation scheme.16 Patients were categorized in 4 differ-
ent groups as follows: Group I, no chondral lesions or Grade I
lesions according to the modiﬁed Outerbridge grading system;
Group II, patients with modiﬁed Outerbridge Grade II lesions;
Group III, patients with modiﬁed Outerbridge Grade III lesions;
and Group IV, patients with modiﬁed Outerbridge Grade IV lesions.Statistical analyses
Data are presented as mean (SD). Kolmogorov-Smirnov test
was used to test the distribution of data and 1-way ANOVA was
applied for determining the between-group differences. A P value
o0.05 was considered signiﬁcant. The group responsible for the
difference was selected using Scheffe test and we used ANCOVA for
multivariate correlation.Table II
Histologic and immunohistochemical ﬁndings.
Group n Biopsy ﬁnding Synovial ﬂu
Normal Chronic synovitis CD30þ
I 19 4 15 1
II 15 3 12 3
III 22 3 19 4
IV 23 4 19 6
Total 79 14 65 14
Ï/2 and P value 0.45/0.92Results
Seventy-nine patients (38 men and 41 women) attending
outpatient clinics due to OA and meniscopathy were included in
this study. Mean (SD) age was 39.2 (7.6) years (range, 26–75 years).
Patients’ chondral lesions detected during arthroscopy were cate-
gorized into 4 different groups based on chondral lesion depth as
determined by the modiﬁed Outerbridge classiﬁcation scheme.
Nineteen Group I, 15 Group II, 22 Group III, and 23 Group IV
patients were evaluated. CD30þ lymphocyte counts were calcu-
lated using ﬂow cytometry on synovial ﬂuid samples obtained at
the time of initial entrance into the joint and compared between
the groups.
In addition, biopsy samples obtained from the suprapatellar
bursa were stained for histologic examination to identify existence
of CD30þ lymphocytes in the synovial tissue.
Signiﬁcantly higher CD30þ T lymphocyte counts were found in
patients with Grade IV chondral lesions (6.28 [2.48]) compared
with those with Grade I, II, or III lesions (2.51 [1.84]; 2.97 [2.40]; or
3.80 [2.07], respectively) (P o 0.05) (Table I).
Histologic presence of CD30þ T lymphocytes could be demon-
strated with immunohistochemical staining of the synovial tissues
in only 1 patient with Grade III lesions. No other patients had
CD30þ cells detected immunohistochemically (see Table II and
the Figure). There were signiﬁcant differences in terms of CD30
levels among the 4 groups. Additionally, there were signiﬁcant
differences in terms of age among the groups. In multivariate
analyses, CD30 levels were correlated with adjusted-for-age and
modiﬁed Outerbridge stages (P o 0.05) (Table I).Discussion
To our knowledge, ours is the ﬁrst study to examine the role of
CD30þ T lymphocytes in the pathogenesis of OA. For this purpose
CD30þ T lymphocyte count was determined in joint ﬂuid samples
from patients undergoing knee arthroscopy, presence of CD30þ T
lymphocytes in synovial tissues was explored with biopsy, and the
association between CD30þ T lymphocyte count and the severity
of arthroscopic chondral lesions was evaluated. Patients with
Grade IV chondral lesions had signiﬁcantly higher CD30þ T
lymphocyte counts compared with the other 3 groups. Except for
a single specimen, histologic examination did not reveal any
CD30þ T lymphocytes in synovial tissues, supporting strong
evidence for the argument that the origin of the CD30þ T
lymphocytes was not the synovial tissue. Thus, we believe that
CD30þ T lymphocytes in the knee joint probably originate from
the damaged chondral tissue and the adjacent subchondral tissue.
CD30þ anaplastic large cell cutaneous lymphomas show a
better prognosis. Thus, CD30 positivity is a very important prog-
nostic factor for T-cell lymphomas of the skin, with CD30 neg-
ativity being associated with a much more aggressive clinical
course and poor prognosis.17id lymphocytes ﬂow-cytometry CD30 immunohistochemistry
CD30– þ Staining
18 0
12 0
18 1
17 0
65 1
Figure. Biopsy sample showing CD30þ T lymphocyte positivity (red circles) in
Group III.
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interleukin-2 receptor, interleukin-10, interferon-γ, tumor necrosis
factor-α, and CD30 was examined in patients with hepatitis B virus
infection. These investigators found higher levels of interferon-γ
and tumor necrosis factor-α during the early stages of the disease
and lower levels during the healing period. On the other hand,
despite higher CD30 levels at early stages, they tend to decrease
with the appearance of the antibody to the hepatitis B surface
antigen and normalization of liver enzymes.
Okumura et al19 found high CD30 levels in patients with certain
autoimmune conditions of the thyroid gland; for example, Hashi-
moto thyroiditis and Grave’s disease. Patients experiencing a thyro-
toxic episode had higher CD30 levels with a sharp decrease after the
thyrotoxic attack. The same authors also regarded CD30 as a reliable
marker for the disease activity for autoimmune conditions.
In light of the abovementioned data, CD30þ T lymphocytes
appear to play a counter-regulatory role in inﬂammatory condi-
tions due to their anti-inﬂammatory effect, ability to regulate the
growth and differentiation of T lymphocytes, and ability to
increase the release of anti-inﬂammatory cytokines from Th2
lymphocytes via CD30 stimulation. Our hypothesis was that there
would be a correlation with CD30 levels and lesion severity in
patients with knee OA.
Most of the histopathologic studies of OA have focused on the
joint cartilage and bone tissue and there is a relative scarcity of
data on synovial reactions, immunopathology, and the role of T
lymphocytes in OA. Focal lymphocyte inﬁltration also occurs in
patients with OA, although not as marked as in patients with
rheumatoid arthritis.
Upper layers of the synovium have been shown to harbor
CD4þ T and CD8þ T lymphocytes in patients with OA or
rheumatoid arthritis, respectively. The synovial inﬂammation
observed in most patients with OA is considered a secondary
process that starts with the release of macromolecules from
cartilage breakdown. Inﬂammation of the synovial membrane
causes increased synthesis of cytokines, which in turn causes
further breakdown of the cartilage and inﬂammation.20
Damage to chondral tissue is related to the inﬂammation of
synovial tissue. In our study, a majority of study patients had
signs of chronic synovitis in their synovial biopsy samples. A
parallel increase in the severity of synovitis is expected with
increased injury in the cartilage. However all groups in our
study had marked synovitis without a signiﬁcant difference.
Particularly in Group IV, where the subchondral tissues are
exposed, the high CD30þ T lymphocyte count could beexplained by an immunologic effort to suppress synovial
inﬂammation.
It has been reported in the literature that the prevalance and
the degree of OA increases with age.21,22 The authors investigated
inﬂammatory factors associated with OA in aged cohort and anti-
inﬂammatory response to inﬂammatory stress may protect against
OA.23 In our study we suggest that increased age may contribute to
depth of chondral lesions and also increased CD30þ T lymphocyte
levels. In addition, CD30 count independently predicted depth of
chondral lesions in our study.
Deeper chondral damage was associated with higher CD30þ T
lymphocyte count in synovial ﬂuid.Conclusions
It appears that CD30þ T lymphocytes may play a role in the
pathogenesis of OA, CD30þ T lymphocytes in synovial tissue
originate from the damaged cartilage and subchondral tissues,
and CD30þ T lymphocytes may play a counter-regulatory role in
the inﬂammatory process in the synovium due to their anti-
inﬂammatory effects.Acknowledgments
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